Targeting RAS-ERK signalling in cancer: Promises and challenges

Nature Reviews Drug Discovery

Volumn 13, Issue 12, 2014, Pages 928-942

  Samatar, Ahmed A ^a   Poulikakos, Poulikos I ^b  

^a TheraMet Biosciences   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN INHIBITOR; RAF PROTEIN INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

BRAF GENE; CANCER RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTATIC MELANOMA; MUTANT; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTEIN KINASE INHIBITORS; RAS PROTEINS;

EID: 84921270388     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4281     Document Type: Review

References (137)

1. Montagut, C. & Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283, 125-134 (2009).
2. Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310 (2007).
3. Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290 (2007).
4. Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2, 232-260 (2011).
5. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
6. V600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385-394 (2011).
7. Baines, A. T., Xu, D. & Der, C. J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3, 1787-1808 (2011).
8. Castellano, E. & Downward, J. RAS Interaction with PI3K: more than just another effector pathway. Genes Cancer 2, 261-274 (2011).
9. Downward, J. Targeting RAS and PI3K in lung cancer. Nature Med. 14, 1315-1316 (2008).
10. Neel, N. F. et al. The RalGEF-Ral effector signaling network: the road less traveled for anti-ras drug discovery. Genes Cancer 2, 275-287 (2011).
11. Young, A. et al. Ras signaling and therapies. Adv. Cancer Res. 102, 1-17 (2009).
12. James, G., Goldstein, J. L. & Brown, M. S. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl Acad. Sci. USA 93, 4454-4458 (1996).
13. Whyte, D. B. et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464 (1997).
14. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
15. Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109, 5299-5304 (2012).
16. Sun, Q. et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. 51, 6140-6143 (2012).
17. Burns, M. C. et al. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl Acad. Sci. USA 111, 3401-3406 (2014).
18. Shima, F. et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl Acad. Sci. USA 11 0, 8182-8187 (2013).
19. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
20. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875-885 (2004).
21. Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595-3598 (2001).
22. Cutler, R. E. Jr., Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214-9219 (1998).
23. Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5, 835-844 (2006).
24. Emuss, V., Garnett, M., Mason, C. & Marais, R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 65, 9719-9726 (2005).
25. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 11 6, 855-867 (2004).
26. Pritchard, C. A., Samuels, M. L., Bosch, E. & McMahon, M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol. Cell. Biol. 15, 6430-6442 (1995).
27. Imielinski, M. et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J. Clin. Invest. 124, 1582-1586 (2014).
28. Nelson, D. S. et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123, 3152-3155 (2014).
29. Chen, J., Fujii, K., Zhang, L., Roberts, T. & Fu, H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783-7788 (2001).
30. O'Neill, E., Rushworth, L., Baccarini, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267-2270 (2004).
31. Wang, S., Ghosh, R. N. & Chellappan, S. P. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol. Cell. Biol. 18, 7487-7498 (1998).
32. Ehrenreiter, K. et al. Raf-1 regulates Rho signaling and cell migration. J. Cell Biol. 168, 955-964 (2005).
33. Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 11 6, 1919-1923 (2010).
34. Haroche, J. et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120, 2700-2703 (2012).
35. Eisen, T. et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586 (2006).
36. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
37. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
38. Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet 379, 1893-1901 (2012).
39. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
40. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
41. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
42. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
43. Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903-14908 (2010).
44. Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell. Melanoma Res. 23, 190-200 (2010).
45. V600E. Mol. Cell 36, 477-486 (2009).
46. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med. 364, 2507-2516 (2011).
47. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med. 363, 809-819 (2010).
48. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93 (2014).
49. Haroche, J. et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121, 1495-1500 (2013).
50. Holderfield, M. et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594-602 (2013).
51. Roring, M. et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31, 2629-2647 (2012).
52. Wu, X. et al. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol. Cell. Biol. 32, 3872-3890 (2012).
53. Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036-1046 (2013).
54. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
55. Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nature Chem. Biol. 9, 428-436 (2013).
56. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
57. Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 49, 751-758 (2013).
58. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. New Engl. J. Med. 366, 207-215 (2012).
59. Callahan, M. K. et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. New Engl. J. Med. 367, 2316-2321 (2012).
60. Abdel-Wahab, O. et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF and NRAS mutant malignancies. Cancer Discov. 4, 538-545 (2014).
61. Carlino, M. S. et al. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2013.51.5783 (2014).
62. Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11-15 (2011).
63. Stuart, D. D. et al. Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. Cancer Res. 72, S1 (2012).
64. Nakamura, A. et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 73, 7043-7055 (2013).
65. Basile, K. J., Le, K., Hartsough, E. J. & Aplin, A. E. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell. Melanoma Res. 27, 479-484 (2014).
66. Sievert, A. J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110, 5957-5962 (2013).
67. Roskoski, R. Jr MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem. Biophys. Res. Commun. 417, 5-10 (2012).
68. Sebolt-Leopold, J. S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Design 10, 1907-1914 (2004).
69. Marks, J. L. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68, 5524-5528 (2008).
70. Murugan, A. K., Dong, J., Xie, J. & Xing, M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8, 2122-2124 (2009).
71. Haura, E. B. et al. A Phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 2450-2457 (2010).
72. Rinehart, J. et al. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462 (2004).
73. Banerji, U. et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a Phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res. 16, 1613-1623 (2010).
74. Lorusso, P. M. et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281-5293 (2005).
75. Brown, A. P., Carlson, T. C., Loi, C. M. & Graziano, M. J. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, D0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59, 671-679 (2007).
76. Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810-816 (1999).
77. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
78. LoRusso, P. M. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924-1937 (2010).
79. Yeh, T. C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583 (2007).
80. Davies, B. R. et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209-2219 (2007).
81. Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008).
82. Leijen, S. et al. A Phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68, 1619-1628 (2011).
83. Kirkwood, J. M. et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555-567 (2012).
84. Janne, P. A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, Phase 2 study. Lancet Oncol. 14, 38-47 (2013).
85. Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000 (2011).
86. Infante, J. R. et al. A Phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur. J. Cancer 49, 2077-2085 (2013).
87. Falchook, G. S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a Phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789 (2012).
88. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl. J. Med. 367, 107-114 (2012).
89. Carlino, M. S. et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol. 8, 544-554 (2014).
90. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl. J. Med. 367, 1694-1703 (2012).
91. Kim, K. et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol. 149, 537-549 (2010).
92. Choo, E. F. et al. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metabolism Dispos. 40, 919-927 (2012).
93. Iverson, C. et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69, 6839-6847 (2009).
94. Hatzivassiliou, G. et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature 501, 232-236 (2013).
95. Dong, Q. et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg. Med. Chem. Lett. 21, 1315-1319 (2011).
96. Martinez-Garcia, M. et al. First-in-human, Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin. Cancer Res. 18, 4806-4819 (2012).
97. Leijen, S. et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin. Cancer Res. 18, 4794-4805 (2012).
98. Ascierto, P. A. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label Phase 2 study. Lancet Oncol. 14, 249-256 (2013).
99. Kim, K. B. et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482-489 (2013).
100. Dougherty, M. K. et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224 (2005).
101. Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806-819 (2010).
102. Fritsche-Guenther, R. et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Systems Biol. 7, 489 (2011).
103. Young, A., Lou, D. & McCormick, F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3, 112-123 (2013).
104. Ishii, N. et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050-4060 (2013).
105. Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697-710 (2014).
106. Boulton, T. G. et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-675 (1991).
107. Haystead, T. A., Dent, P., Wu, J., Haystead, C. M. & Sturgill, T. W. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett. 306, 17-22 (1992).
108. Aronov, A. M. et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362-6368 (2009).
109. Hatzivassiliou, G. et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11, 1143-1154 (2012).
110. Ohori, M. et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 336, 357-363 (2005).
111. Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
112. Sullivan, R. J. & Flaherty, K. T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49, 1297-1304 (2013).
113. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
114. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
115. Montero-Conde, C. et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3, 520-533 (2013).
116. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
117. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
118. Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682 (2012).
119. Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122 (2014).
120. Whittaker, S. R. et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350-362 (2013).
121. Maertens, O. et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, 338-349 (2013).
122. Nissan, M. H. et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74, 2340-2350 (2014).
123. Lin, L. et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl Acad. Sci. USA 111, E748-E757 (2014).
124. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
125. V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3, 724 (2012).
126. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
127. Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167 (2012).
128. Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
129. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
130. Marusiak, A. A. et al. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nature Commun. 5, 3901 (2014).
131. Emery, C. M. et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416 (2009).
132. Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68 (2014).
133. Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Onc. Abstr. 28, 3534 (2010).
134. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
135. Carlino, M. S. et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol. Cancer Ther. 12, 1332-1342 (2013).
136. Deng, Y. et al. Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase. J.Med.Chem http://dx.doi. org/10.1021/jm500847m (2014).
137. Chaikuad, A. et al. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nature Chem. Biol. 10, 853-860 (2014).